诺华-话题@MedSci

#诺华#

235篇内容 | 4969人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2126336, encodeId=67fd2126336cc, content=好奇<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a> <a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a><a href='/topic/show?id=d61a9261957' target=_blank style='color:#2F92EE;'>#赛诺菲#</a><a href='/topic/show?id=e0df9e832a7' target=_blank style='color:#2F92EE;'>#阿斯利康#</a><a href='/topic/show?id=4c2ce960918' target=_blank style='color:#2F92EE;'>#罗氏#</a><a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>这些大公司在中国的知名度，看看它们的围观人数，是不是成正比！, objectTitle=辉瑞, objectType=topic, longId=93725, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=1, likeNumber=161, createdTime=2023-04-16, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=香港, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282832, encodeId=c60e12828329d, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华与 Precision合作开发潜在的镰状细胞性贫血基因治疗, objectType=article, longId=730268, objectId=6578e302681b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6578e302681b, replyNumber=0, likeNumber=87, createdTime=2022-06-24, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6578e302681b, moduleTitle=诺华与 Precision合作开发潜在的镰状细胞性贫血基因治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6578e302681b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282831, encodeId=0bf81282831b2, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=今日探报 | 诺华长效降脂siRNA疗法获FDA批准上市；研究表明，利用一滴血或许就能快速检测出早期肺癌……, objectType=article, longId=292887, objectId=627029288e90, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=627029288e90, replyNumber=0, likeNumber=81, createdTime=2021-12-29, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=627029288e90, moduleTitle=今日探报 | 诺华长效降脂siRNA疗法获FDA批准上市；研究表明，利用一滴血或许就能快速检测出早期肺癌……, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=627029288e90)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282830, encodeId=41741282830fa, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的ligelizumab在自发性荨麻疹研究中未能击败Xolair, objectType=article, longId=292585, objectId=104d2925856a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=104d2925856a, replyNumber=0, likeNumber=75, createdTime=2021-12-24, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=104d2925856a, moduleTitle=诺华的ligelizumab在自发性荨麻疹研究中未能击败Xolair, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=104d2925856a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282829, encodeId=31e012828291d, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=全人源CD20单抗！诺华多发性硬化新药奥法妥木单抗在中国获批, objectType=article, longId=292522, objectId=095329252292, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=095329252292, replyNumber=0, likeNumber=98, createdTime=2021-12-24, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=095329252292, moduleTitle=全人源CD20单抗！诺华多发性硬化新药奥法妥木单抗在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=095329252292)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282828, encodeId=ec7e128282869, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=治疗C3肾小球肾炎，诺华的 iptacopan 在中期研究中达到临床终点, objectType=article, longId=220407, objectId=751922040e38, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=751922040e38, replyNumber=0, likeNumber=88, createdTime=2021-11-17, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=751922040e38, moduleTitle=治疗C3肾小球肾炎，诺华的 iptacopan 在中期研究中达到临床终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=751922040e38)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282827, encodeId=a679128282e44, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华宣布FDA接受Beovu治疗糖尿病黄斑水肿患者的申请, objectType=article, longId=218746, objectId=47b2218e46d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47b2218e46d3, replyNumber=0, likeNumber=91, createdTime=2021-10-18, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47b2218e46d3, moduleTitle=诺华宣布FDA接受Beovu治疗糖尿病黄斑水肿患者的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47b2218e46d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282826, encodeId=a49812828266e, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=北京病痛挑战公益基金会携手诺华制药联合发布全国首部多发性硬化患者纪录片《让爱可及》, objectType=article, longId=207774, objectId=d8ba20e774c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8ba20e774c7, replyNumber=0, likeNumber=88, createdTime=2021-03-02, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8ba20e774c7, moduleTitle=北京病痛挑战公益基金会携手诺华制药联合发布全国首部多发性硬化患者纪录片《让爱可及》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8ba20e774c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282825, encodeId=90521282825af, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=慢性自发性荨麻疹(CSU)新药！诺华新一代IgE抗体ligelizumab获美国FDA突破性药物资格!, objectType=article, longId=205804, objectId=2e6320580469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e6320580469, replyNumber=0, likeNumber=85, createdTime=2021-01-18, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e6320580469, moduleTitle=慢性自发性荨麻疹(CSU)新药！诺华新一代IgE抗体ligelizumab获美国FDA突破性药物资格!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e6320580469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282824, encodeId=2e4212828243b, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华支付6.5亿美元用于百济神州抗PD-1药物tislelizumab的海外使用权, objectType=article, longId=205683, objectId=7caf20568388, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7caf20568388, replyNumber=0, likeNumber=87, createdTime=2021-01-14, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7caf20568388, moduleTitle=诺华支付6.5亿美元用于百济神州抗PD-1药物tislelizumab的海外使用权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7caf20568388)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282823, encodeId=ca3f128282334, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=美国FDA延迟批准诺华的siRNA药物inclisiran, objectType=article, longId=204702, objectId=1eb3204e028a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1eb3204e028a, replyNumber=0, likeNumber=87, createdTime=2020-12-21, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1eb3204e028a, moduleTitle=美国FDA延迟批准诺华的siRNA药物inclisiran, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1eb3204e028a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282822, encodeId=fe661282822d0, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=药代备案制后，诺华、罗氏调整团队, objectType=article, longId=204103, objectId=e26120410318, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e26120410318, replyNumber=0, likeNumber=82, createdTime=2020-12-05, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e26120410318, moduleTitle=药代备案制后，诺华、罗氏调整团队, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e26120410318)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282821, encodeId=be0812828214f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=NICE拒绝了诺华的Adakveo（crizanlizumab）, objectType=article, longId=203864, objectId=69b5203864d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69b5203864d9, replyNumber=0, likeNumber=94, createdTime=2020-12-01, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69b5203864d9, moduleTitle=NICE拒绝了诺华的Adakveo（crizanlizumab）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69b5203864d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282820, encodeId=956d12828209f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=无论年龄和性别，诺华靶向PCSK9的siRNA疗法均可在17个月内持续有效降低LDL-C, objectType=article, longId=203468, objectId=f49f20346875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f49f20346875, replyNumber=0, likeNumber=108, createdTime=2020-11-18, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f49f20346875, moduleTitle=无论年龄和性别，诺华靶向PCSK9的siRNA疗法均可在17个月内持续有效降低LDL-C, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f49f20346875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282819, encodeId=44a41282819c8, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华IL-1β单抗canakinumab治疗新冠COVID-19：未能提高生存率, objectType=article, longId=203185, objectId=8a9e203185f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a9e203185f0, replyNumber=0, likeNumber=79, createdTime=2020-11-11, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a9e203185f0, moduleTitle=诺华IL-1β单抗canakinumab治疗新冠COVID-19：未能提高生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a9e203185f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282818, encodeId=1067128281880, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=直击进博会丨诺华肿瘤和阿里健康达成合作，打造数字化医疗创新闭环, objectType=article, longId=203052, objectId=12732030528c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12732030528c, replyNumber=0, likeNumber=0, createdTime=2020-11-09, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12732030528c, moduleTitle=直击进博会丨诺华肿瘤和阿里健康达成合作，打造数字化医疗创新闭环, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12732030528c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282817, encodeId=12d8128281efb, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的Ilaris无法降低COVID-19患者的死亡率, objectType=article, longId=203010, objectId=f0a3203010db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0a3203010db, replyNumber=0, likeNumber=85, createdTime=2020-11-08, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0a3203010db, moduleTitle=诺华的Ilaris无法降低COVID-19患者的死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0a3203010db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282816, encodeId=557712828162e, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的IL-17A单抗Cosentyx在银屑病关节炎III期研究中显著减轻滑膜炎, objectType=article, longId=202989, objectId=b8be20298966, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8be20298966, replyNumber=0, likeNumber=103, createdTime=2020-11-08, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8be20298966, moduleTitle=诺华的IL-17A单抗Cosentyx在银屑病关节炎III期研究中显著减轻滑膜炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8be20298966)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282815, encodeId=c46a128281594, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=降脂神药！一年给药2次，药效持续17个月，诺华的siPCSK9疗法inclisiran获得欧洲CHMP的正面评价, objectType=article, longId=202221, objectId=a2c720222179, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2c720222179, replyNumber=0, likeNumber=92, createdTime=2020-10-18, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2c720222179, moduleTitle=降脂神药！一年给药2次，药效持续17个月，诺华的siPCSK9疗法inclisiran获得欧洲CHMP的正面评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2c720222179)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282814, encodeId=1ab5128281481, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=靶向ADAMTS5骨关节炎新型纳米抗体，默克以5000万欧元授予给诺华, objectType=article, longId=201991, objectId=5d832019917b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d832019917b, replyNumber=0, likeNumber=88, createdTime=2020-10-13, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d832019917b, moduleTitle=靶向ADAMTS5骨关节炎新型纳米抗体，默克以5000万欧元授予给诺华, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d832019917b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

诺华

2020-05-29发表于威斯康星

侠胆医心 (审核中...)

前往app查看评论内容

好奇#辉瑞# #诺华##赛诺菲##阿斯利康##罗氏##杨森#这些大公司在中国的知名度，看看它们的围观人数，是不是成正比！

2023-04-16发表于香港

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华与 Precision合作开发潜在的镰状细胞性贫血基因治疗

2022-06-24

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

今日探报 | 诺华长效降脂siRNA疗法获FDA批准上市；研究表明，利用一滴血或许就能快速检测出早期肺癌……

2021-12-29

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的ligelizumab在自发性荨麻疹研究中未能击败Xolair

2021-12-24

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

全人源CD20单抗！诺华多发性硬化新药奥法妥木单抗在中国获批

2021-12-24

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

治疗C3肾小球肾炎，诺华的 iptacopan 在中期研究中达到临床终点

2021-11-17

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华宣布FDA接受Beovu治疗糖尿病黄斑水肿患者的申请

2021-10-18

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

北京病痛挑战公益基金会携手诺华制药联合发布全国首部多发性硬化患者纪录片《让爱可及》

2021-03-02

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

慢性自发性荨麻疹(CSU)新药！诺华新一代IgE抗体ligelizumab获美国FDA突破性药物资格!

2021-01-18

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华支付6.5亿美元用于百济神州抗PD-1药物tislelizumab的海外使用权

2021-01-14

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

美国FDA延迟批准诺华的siRNA药物inclisiran

2020-12-21

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

药代备案制后，诺华、罗氏调整团队

2020-12-05

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

NICE拒绝了诺华的Adakveo（crizanlizumab）

2020-12-01

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

无论年龄和性别，诺华靶向PCSK9的siRNA疗法均可在17个月内持续有效降低LDL-C

2020-11-18

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华IL-1β单抗canakinumab治疗新冠COVID-19：未能提高生存率

2020-11-11

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

直击进博会丨诺华肿瘤和阿里健康达成合作，打造数字化医疗创新闭环

2020-11-09

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的Ilaris无法降低COVID-19患者的死亡率

2020-11-08

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的IL-17A单抗Cosentyx在银屑病关节炎III期研究中显著减轻滑膜炎

2020-11-08

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

降脂神药！一年给药2次，药效持续17个月，诺华的siPCSK9疗法inclisiran获得欧洲CHMP的正面评价

2020-10-18

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

靶向ADAMTS5骨关节炎新型纳米抗体，默克以5000万欧元授予给诺华

2020-10-13

科室
- - 订阅+
  - 更多科室
工具
服务